



**UPF 1069** 

Catalog No: tcsc1466



## **Available Sizes**

Size: 10mg

Size: 50mg



## **Specifications**

CAS No:

1048371-03-4

Formula:

 $C_{17}H_{13}NO_{3}$ 

**Pathway:** 

Epigenetics; Cell Cycle/DNA Damage

**Target:** 

PARP;PARP

**Purity / Grade:** 

>98%

**Solubility:** 

DMSO :  $\geq$  100 mg/mL (358.05 mM)

**Observed Molecular Weight:** 

279.29

## **Product Description**

UPF 1069 is a **PARP** inhibitor, with  $IC_{50}$ s of 8 and 0.3  $\mu$ M for PARP-1 and PARP-2, respectively.

IC50 & Target: IC50: 8  $\mu$ M (PARP-1), 0.3  $\mu$ M (PARP-2)<sup>[1][2]</sup>

In Vitro: UPF 1069 (Compound 55) is a PARP inhibitor, with  $IC_{50}$ s of 8 and 0.3  $\mu$ M for PARP-1 and PARP-2, respectively<sup>[1]</sup>. UPF 1069 (1  $\mu$ M) reduces the residual PARP activity by approximately 80% of PARP-1-deficient fibroblasts, but only slightly inhibits the enzymic





activity in wild-type fibroblasts. UPF 1069 (0.1-1  $\mu$ M) markedly enhances CA1 hippocampal damage. UPF 1069 (10  $\mu$ M) also exacerbates oxygen-glucose deprivation (OGD) damage in organotypic hippocampal slices. However, UPF 1069 alleviates the damage cuased by OGD in mixed cortical cell cultures, shows a potent neuroprotective activity both at a concentration (1  $\mu$ M) selectively acting on PARP-2 and at a concentration (10  $\mu$ M) inhibiting both PARP-1 and PARP-2 activities<sup>[2]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!